Current Edition

Patenting Antibodies at the European Patent Office

With antibodies accounting for seven out of the top ten global drugs, it is of critical importance that those companies that invest huge sums of money into R&D in this technology space are able to protect their investment from unlawful competition. Hazel Ford and Martin MacLean at Mathys & Squire focus on the European Patent Office (EPO), and on the key issues, you will likely need to address, in order to obtain patent protection in Europe for a new antibody therapeutic.

[wonderplugin_pdf src=”https://www.biopharmaceuticalmedia.com/wp-content/uploads/2020/10/Patenting-Antibodies-at-the-European-Patent-Office.pdf” width=”100%” height=”900px” style=”border:0;”]